Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RIGL 
Rigel Pharmaceuticals Inc (RIGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RIGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $38.33
1 Year Target Price $38.33
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.3% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 708.70M USD | Price to earnings Ratio 7.28 | 1Y Target Price 38.33 |
Price to earnings Ratio 7.28 | 1Y Target Price 38.33 | ||
Volume (30-day avg) 6 | Beta 1.21 | 52 Weeks Range 11.96 - 39.68 | Updated Date 08/15/2025 |
52 Weeks Range 11.96 - 39.68 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.03 | Actual 3.28 |
Profitability
Profit Margin 36.51% | Operating Margin (TTM) 60.09% |
Management Effectiveness
Return on Assets (TTM) 39.01% | Return on Equity (TTM) 37.61% |
Valuation
Trailing PE 7.28 | Forward PE 8.72 | Enterprise Value 661369303 | Price to Sales(TTM) 2.65 |
Enterprise Value 661369303 | Price to Sales(TTM) 2.65 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 6.05 | Shares Outstanding 17937300 | Shares Floating 16168718 |
Shares Outstanding 17937300 | Shares Floating 16168718 | ||
Percent Insiders 2.65 | Percent Institutions 78.5 |
Upturn AI SWOT
Rigel Pharmaceuticals Inc
Company Overview
History and Background
Rigel Pharmaceuticals Inc. was founded in 1996. It is a biotechnology company focused on discovering and developing novel, small-molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer, and rare diseases.
Core Business Areas
- Hematology/Oncology: Discovery and development of small-molecule drugs for hematologic disorders, cancer, and rare diseases.
- Immunology: Research and development of therapies targeting immunological pathways.
Leadership and Structure
Rigel is led by a management team with expertise in drug development and commercialization. The organizational structure includes research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Tavalisse (fostamatinib): Tavalisse is a spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. Competitors include Amgen's Nplate and Novartis's Revolade. While specific market share data fluctuates, Tavalisse competes in the ITP market, which is estimated to be a multi-billion dollar market.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. There's a growing demand for novel therapeutics for unmet medical needs, especially in autoimmune diseases and cancer.
Positioning
Rigel is positioned as a developer of novel, small-molecule drugs targeting specific disease pathways. Its competitive advantage lies in its SYK inhibitor technology and focus on niche markets with high unmet needs.
Total Addressable Market (TAM)
The TAM for Rigel's primary focus areas (ITP, autoimmune diseases, cancer) is substantial, potentially exceeding $50 billion. Rigel is strategically focused on specific niches within these larger markets.
Upturn SWOT Analysis
Strengths
- Proprietary SYK inhibitor technology
- Approved product (Tavalisse)
- Experienced management team
- Strong pipeline of drug candidates
Weaknesses
- Limited commercial infrastructure
- Reliance on a single approved product
- High R&D expenses
- Dependence on partners for certain aspects of drug development
Opportunities
- Expansion of Tavalisse indications
- Development of new drug candidates in the pipeline
- Strategic partnerships and collaborations
- Growing demand for novel therapies in niche markets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AMGN
- NVS
- SNY
Competitive Landscape
Rigel faces competition from larger, more established pharmaceutical companies. Its advantage lies in its targeted therapies and focus on niche markets, but it is disadvantaged by its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by Tavalisse sales and pipeline progress.
Future Projections: Analyst projections vary but generally anticipate growth driven by increased Tavalisse sales, potential new indications, and pipeline advancement.
Recent Initiatives: Recent initiatives include ongoing clinical trials for fostamatinib in additional indications, and advancement of other pipeline candidates.
Summary
Rigel Pharmaceuticals is a biotechnology company with an approved product, Tavalisse, and a pipeline of drug candidates. Its strength lies in its SYK inhibitor technology and focus on niche markets. However, it faces challenges related to competition, commercial infrastructure, and reliance on a single product. Future success depends on expanding Tavalisse indications and advancing its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rigel Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data are estimates and may vary. Financial data should be verified through official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rigel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2000-11-29 | President, CEO & Director Mr. Raul R. Rodriguez | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://www.rigel.com |
Full time employees 162 | Website https://www.rigel.com | ||
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.